Table 1 Characteristics of included studies
Trials | Year | Country | NCT No | Patients | Time range (weeks) | Sample size | Mean age (Years) | Gender (Male/female) | Duration of diabetes (Years) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | Dapagliflozin | Placebo | Dapagliflozin | Placebo | Dapagliflozin | Placebo | Dapagliflozin | Placebo | ||||||
Bays | 2017 | North America-U.S.A | NA | T2D*# | 24 | 4401 | 2237 | 2164 | 59 (± 15.4) | 60.1 (± 15.9) | 1280/957 | 1254/910 | 9.1 | 9 |
Cahn | 2021 | Europe-Polycentric | NCT01730534 | T2D*# | 201.6 | 10,186 | 5108 | 5078 | 64.8 (± 5.7) | 64.8 (± 5.6) | 2874/2234 | 2839/2239 | 11.8 | 11.9 |
Fadini | 2017 | Europe-Italy | NCT02327039 | T2D*# | 12 | 31 | 15 | 16 | 66.3 (± 1.8) | 61 (± 1.8) | 10/5 | 11/5 | 14.2 | 13.9 |
Faerch | 2021 | Oceania-Australia | NCT02695810 | T2D# | 26 | 60 | 30 | 30 | 61.4 (± 8.5) | 57.2 (± 9.9) | 13/17 | 12/18 | –- | –- |
Hardy | 2013 | North America-U.S.A | NA | T2D# | 24 | 2586 | 1193 | 1393 | – | – | – | – | –- | –- |
Jiang | 2021 | Asia-China | CTR20150102 | T2D# | 24 | 29 | 19 | 10 | 58.3 (± 8.01) | 59.3 (± 9.03) | 9/11 | 2/8 | 7.9 | 7.8 |
Leiter | 2016 | North America-Canada | NCT01031680, NCT01042977 | T2D* | 104 | 568 | 284 | 284 | 63.0 (± 7.3) | 62.8 (± 7.4) | 197/87 | 208/76 | 12.7 | 11.8 |
Nur Aisyah | 2020 | Asia-Malaysia | NA | T2D# | 12 | 72 | 36 | 36 | 57.25 (± 8.49) | 58.0 (± 7.32) | 28/8 | 27/9 | 8.94 | 10.72 |
Papadopoulou | 2021 | Europe-Greece | NCT02887677 | T2D# | 12 | 85 | 43 | 42 | 61.74 (± 6.73) | 60.64 (± 9.35) | 23/20 | 21/21 | –- | –- |
Shigiyama | 2017 | Asia-Japan | UMIN000018754 | T2D# | 16 | 74 | 37 | 37 | 57.9 (± 8.3) | 59.4 (± 10.1) | 25/12 | 22/15 | 5.4 | 6.3 |
Sugiyama | 2018 | Asia-Japan | UMIN0000333354 | T2D# | 24 | 54 | 27 | 27 | 55.2 (± 8.7) | 56.0 (± 8.0) | 19/8 | 20/7 | 10.0 | 11.0 |
Weber | 2016 | North America-U.S.A | NCT01137474 | T2D# | 12 | 613 | 302 | 311 | 55.6 (± 8.4) | 56.2 (± 8.9) | 179/123 | 171/140 | 8.2 | 7.6 |
Trials | BMI (Kg/m2) | SBP(mmHg) | DBP(mmHg) | HbA1c(%) | eGFR(mL/min/1.73m2) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Dapagliflozin | Placebo | Dapagliflozin | Placebo | Dapagliflozin | Placebo | Dapagliflozin | Placebo | Dapagliflozin | Placebo | |
Bays | 32.3 (± 5.6) | 32.2 (± 5.7) | 131.7 (± 15.3) | 131.8 (± 14.9) | – | – | 8.2 (± 0.9) | 8.2 (± 0.9) | 81.6 (± 19.1) | 81.2 (± 19.1) |
Cahn | 32 (± 5.9) | 32 (± 6.1) | 135.7(± 15.0) | 135.5(± 15.2) | 78.4(± 8.9) | 78.4(± 8.8) | 8.3(± 1.2) | 8.3(± 1.2) | 85.4(± 15.2) | 85.8(± 14.8) |
Fadini | 28.4(± 1.4) | 32.8(± 1.4) | – | – | – | – | 8.2(± 0.2) | 8.2(± 0.2) | 89.3(± 4.4) | 92.5(± 4.4) |
Faerch | 30.9(± 4.5) | 32.6(± 6.7) | 135(± 14.0) | 135 (± 17) | 85 (± 7.0) | 87 (± 8.0) | 5.9 (± 0.19) | 5.9 (± 0.26) | 84 (± 8.0) | 85 (± 7.0) |
Hardy | 32.4 (± 4.4) | 32.4 (± 4.3) | – | – | – | – | – | – | 82.1 (± 13.7) | 81.9 (± 13.7) |
Jiang | 26.6 (± 1.32) | 25.64 (± 1.41) | 123.2 (± 20.27) | 120 (± 4.25) | 78.16 (± 7.97) | 80.2 (± 9.31) | 8.1 (± 0.3) | 8.5 (± 0.22) | 77.2 (± 13.3) | 76.1 (± 13.0) |
Leiter | 33.1 (± 5.3) | 32.3 (± 5.6) | 133.9 (± 13.9) | 133.7 (± 13.2) | 78 (± 8.3) | 77.2 (± 8.6) | 8.1 (± 0.8) | 8.1 (± 0.8) | 79.74 (−) | 79.74 (-) |
Nur Aisyah | 27.49 (± 4.1) | 29.85 (± 4.23) | 140.92 (± 22.07) | 141.06 (± 21.61) | 78.31 (± 11.17) | 77.86 (± 12.78) | 9.66 (± 1.86) | 9.31 (± 1.58) | 85.24 (± 18.69) | 82.31 (± 15.66) |
Papadopoulou | 31.33 (± 4.5) | 31.83 (± 7.08) | 129 (± 12.6) | 129 (± 12.4) | 77.3 (± 7.3) | 78.9 (± 8.7) | 7.75 (± 0.57) | 7.75 (± 0.42) | 101.33 (± 20.85) | 95.02 (± 20.05) |
Shigiyama | 26.8 (± 4.6) | 26.3 (± 3.5) | 129.2 (± 13.7) | 130 (± 12.4) | 81.8 (± 9.6) | 79.9 (± 8.5) | 6.8 (± 0.5) | 6.9 (± 0.5) | 84.1 (± 19.5) | 83.4 (± 17.2) |
Sugiyama | 27.6 (± 2.2) | 26.5 (± 3.1) | 130.3 (± 15.3) | 131 (± 13.4) | 78 (± 8.3) | 76.3 (± 7.5) | 7.9 (± 0.4) | 8 (± 0.3) | 75.4 (± 15.4) | 73.2 (± 11.8) |
Weber | 30.21 (± 4.3) | 29.52 (± 3.3) | 149.8 (± 7.5) | 149.5 (± 8.0) | 91.1 (± 4.8) | 90.8 (± 4.9) | 8.1 (± 1.0) | 8 (± 0.9) | 85.1 (± 18.9) | 86.7 (± 19.4) |